Label expansion approval for Iclusig (ponatinib) addresses adult patients with newly diagnosed Philadelphia chromosome–positive acute lymphoblastic leukemia.
FDA Grants Accelerated Approval to Takeda's Iclusig for Ph-Positive Acute Lymphoblastic Leukemia
Posted on by admin
![](https://onclive.s3.amazonaws.com/onclive_630x1200.png)
1 min read
+ There are no comments
Add yours